Monthly Archives: November 2018

NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab

2020-03-02T20:05:42+00:00November 1st, 2018|Categories: News|Tags: |

With the recent patent expiry of Humira® (adalimumab) in Europe, NHS England last week published a press release reiterating their goal of realizing £300 million in annual savings through the adoption of best value biologic medicines (originator or biosimilar) by 2021. With more than 46,000 patients in the UK and an annual cost of greater than £400 million, Humira represents the largest spend on a single drug by the NHS and a significant opportunity [...]

Comments Off on NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab

Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market

2020-02-26T14:02:40+00:00November 1st, 2018|Categories: Blog|Tags: , |

Although biosimilars have taken off in Europe, they have yet to gain significant traction in the United States. More than thirty biosimilars have been approved and twenty-six are marketed in Europe. In the US, there are only eleven biosimilars approved with only five marketed: Zarxio, Fulphila, Retacrit, Renflexis, and Inflectra. Read the full report by downloading this paper. Download White Paper